SKY-0515 data suggest slower progression in Huntington’s disease

SKY-0515 data suggest slower progression in Huntington’s disease

June 3, 2026 discoverhiddenusacom Health

New interim data from a clinical trial suggest that an investigational oral therapy, SKY-0515, may slow the progression of Huntington’s disease. In the Phase 1/2 study, individuals with early-stage Huntington’s who received the treatment showed clinical outcomes that diverged positively from the expected trajectory of the disease.

Huntington’s is a progressive, neurodegenerative condition caused by mutations in the HTT gene. These mutations trigger the production of a mutant huntingtin (HTT) protein, which is understood to drive the disease. SKY-0515 works by targeting RNA to reduce levels of both normal and mutant HTT, as well as PMS1, a DNA-repair protein linked to disease progression.

Understanding the Clinical Significance

The study utilized the Composite Unified Huntington’s Disease Rating Scale (cUHDRS) to measure motor function, cognitive performance, and daily functional ability. While natural history data suggest that patients typically experience a decline of 0.92 points on this scale over one year, participants treated with SKY-0515 showed an average improvement of 0.38 points after one year of treatment.

Understanding the Clinical Significance
Phase

Beyond clinical scores, the therapy demonstrated a notable impact on biological markers. Blood levels of the mutant HTT protein were reduced by up to 69%, while PMS1 mRNA levels dropped by up to 26%. According to researchers, these results suggest that the treatment is well tolerated and offers a potential for meaningful therapeutic impact.

Did You Know? The ongoing FALCON-HD trial, which is testing SKY-0515 against a placebo, has already completed its Australian and New Zealand enrollment phase ahead of schedule with 144 participants.

The Path Forward

The development of SKY-0515 is currently moving into larger testing phases. The FALCON-HD programme is actively recruiting up to 400 participants across eight countries, including Georgia and Argentina. This trial is designed to evaluate the therapy’s effect on cUHDRS scores, brain volume, and mHTT levels over a 1.5-year period.

What SKY-0515 could mean for the Huntington's Disease community across the globe?

Depending on future results, the worldwide portion of the FALCON-HD trial is expected to be completed by 2029. If the current trends of clinical improvement and biomarker reduction are sustained in these larger, placebo-controlled studies, SKY-0515 could represent a transformative option for the global Huntington’s disease community.

Expert Insight: The significance of these findings lies in the dual approach of lowering the mutant protein while also addressing the PMS1 protein. By targeting the underlying molecular drivers of the disease, the trial aims to shift the clinical trajectory of patients. However, as the research moves into larger Phase 2/3 trials, the primary focus will be confirming whether these early biomarker reductions reliably translate into long-term functional stability for patients.

Frequently Asked Questions

What is the primary mechanism of SKY-0515?
SKY-0515 is an oral therapy designed to target RNA to reduce levels of both normal and mutant HTT proteins, as well as the DNA-repair protein PMS1.

How did the treated participants compare to natural history data?
While natural history data indicate an expected decline of 0.92 points on the cUHDRS scale over one year, treated participants showed an average improvement of 0.38 points over the same period.

When is the worldwide FALCON-HD trial expected to conclude?
The worldwide portion of the FALCON-HD trial is anticipated to be completed in 2029.

What role do you believe oral therapies will play in the future of managing neurodegenerative conditions?